CA3149853A1 - Treatment and prevention of cancer using her3 antigen-binding molecules - Google Patents

Treatment and prevention of cancer using her3 antigen-binding molecules Download PDF

Info

Publication number
CA3149853A1
CA3149853A1 CA3149853A CA3149853A CA3149853A1 CA 3149853 A1 CA3149853 A1 CA 3149853A1 CA 3149853 A CA3149853 A CA 3149853A CA 3149853 A CA3149853 A CA 3149853A CA 3149853 A1 CA3149853 A1 CA 3149853A1
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
antigen
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3149853A
Other languages
English (en)
French (fr)
Inventor
Jerome Douglas BOYD-KIRKUP
Siyu GUAN
Piers INGRAM
Konrad PASZKIEWICZ
Vicente SANCENON
Dipti THAKKAR
Zhihao WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hummingbird Bioscience Holdings Ltd
Original Assignee
Hummingbird Bioscience Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hummingbird Bioscience Holdings Ltd filed Critical Hummingbird Bioscience Holdings Ltd
Publication of CA3149853A1 publication Critical patent/CA3149853A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3149853A 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules Pending CA3149853A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1913079.8A GB201913079D0 (en) 2019-09-11 2019-09-11 Treatment and prevention of cancer using her3 antigen-binding molecules
GB1913079.8 2019-09-11
PCT/EP2020/075319 WO2021048274A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules

Publications (1)

Publication Number Publication Date
CA3149853A1 true CA3149853A1 (en) 2021-03-18

Family

ID=68241208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3149853A Pending CA3149853A1 (en) 2019-09-11 2020-09-10 Treatment and prevention of cancer using her3 antigen-binding molecules

Country Status (16)

Country Link
US (3) US11208498B2 (cg-RX-API-DMAC7.html)
EP (2) EP3943509A1 (cg-RX-API-DMAC7.html)
JP (2) JP7708741B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220086554A (cg-RX-API-DMAC7.html)
CN (2) CN113347994B (cg-RX-API-DMAC7.html)
AU (1) AU2020347473B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004474A8 (cg-RX-API-DMAC7.html)
CA (1) CA3149853A1 (cg-RX-API-DMAC7.html)
DK (1) DK3818086T3 (cg-RX-API-DMAC7.html)
ES (1) ES2896921T3 (cg-RX-API-DMAC7.html)
GB (1) GB201913079D0 (cg-RX-API-DMAC7.html)
MX (1) MX2022002977A (cg-RX-API-DMAC7.html)
PL (1) PL3818086T3 (cg-RX-API-DMAC7.html)
PT (1) PT3818086T (cg-RX-API-DMAC7.html)
TW (1) TWI883044B (cg-RX-API-DMAC7.html)
WO (1) WO2021048274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3023551T3 (en) 2016-03-25 2025-06-02 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN109563166B (zh) * 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
AU2018241881B2 (en) 2017-03-27 2024-10-10 Biomunex Pharmaceuticals Stable multispecific antibodies
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
CN114790462B (zh) * 2021-01-25 2023-10-31 中国医学科学院血液病医院(中国医学科学院血液学研究所) 靶向bcma的嵌合抗原受体及其应用
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
WO2022192534A1 (en) * 2021-03-11 2022-09-15 Elevation Oncology, Inc. Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions
TW202313972A (zh) * 2021-06-03 2023-04-01 荷蘭商美勒斯公司 新nrg1融合物、融合接合處及檢測彼等之方法
WO2022255869A2 (en) * 2021-06-03 2022-12-08 Merus N.V. Liquid biopsy assays for detecting nrg1 fusion polynucleotides
GB202108449D0 (en) 2021-06-14 2021-07-28 Hummingbird Bioscience Holdings Pte Ltd Cells expressing her3 antigen-binding molecules
JP2024529141A (ja) 2021-08-13 2024-08-01 ハミングバード・バイオサイエンス・プライベート・リミテッド Her3抗原結合性分子を使用したがんの処置および予防
CN118541395A (zh) * 2021-09-03 2024-08-23 癌症研究科技有限公司 用her3抗原结合分子治疗和预防癌症
CN116333118B (zh) * 2021-12-16 2024-04-19 徕特康(苏州)生物制药有限公司 抗表皮生长因子受体抗体及其制备方法和用途
IL315262A (en) * 2022-03-03 2024-10-01 Pfizer Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses
WO2024121163A1 (en) 2022-12-06 2024-06-13 Cancer Research Technology Limited Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers
WO2024121226A1 (en) 2022-12-07 2024-06-13 Hummingbird Bioscience Pte. Ltd. Combination for treatment and prevention of cancer
CN120857946A (zh) 2023-01-03 2025-10-28 蜂鸟生物科技私人有限公司 Her3结合抗体-药物缀合物
KR20260026009A (ko) 2023-04-06 2026-02-25 허밍버드 바이오사이언스 피티이. 엘티디. Her3 항원 결합 분자를 이용한 암의 치료 및 예방
KR20260022498A (ko) 2023-04-14 2026-02-19 허밍버드 바이오사이언스 피티이. 엘티디. 암의 치료 및 예방을 위한 조합물
WO2025057173A2 (en) * 2023-09-14 2025-03-20 B.G. Negev Technologies And Applications Ltd. Ligand-based chimeric antigen receptors and uses thereof
CN122206706A (zh) 2023-09-15 2026-06-12 蜂鸟生物科技私人有限公司 使用her3结合分子治疗和预防癌症

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
KR20150036824A (ko) * 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-her 항체
US9932403B2 (en) 2010-05-20 2018-04-03 Ablynx Nv Biological materials related to HER3
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
WO2013148315A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10239951B2 (en) * 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
US20160319253A1 (en) 2013-12-19 2016-11-03 National Cancer Center Novel fusion genes as factors responsible for gastric cancer
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
AR103268A1 (es) * 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ NRG1融合遺伝子を有する細胞の処置における使用のためのErbB-2及びErbB3結合二重特異性抗体
CN111527103A (zh) 2017-09-08 2020-08-11 科罗拉多大学董事会,法人团体 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2019185164A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules

Also Published As

Publication number Publication date
US20210155712A1 (en) 2021-05-27
DK3818086T3 (da) 2021-10-04
CN116059347A (zh) 2023-05-05
KR20220086554A (ko) 2022-06-23
EP3818086B1 (en) 2021-08-04
GB201913079D0 (en) 2019-10-23
TWI883044B (zh) 2025-05-11
US11208498B2 (en) 2021-12-28
ES2896921T3 (es) 2022-02-28
AU2020347473B2 (en) 2026-07-16
AU2020347473A1 (en) 2022-03-31
PT3818086T (pt) 2021-10-26
MX2022002977A (es) 2022-07-12
JP2022548057A (ja) 2022-11-16
US20220153870A1 (en) 2022-05-19
EP3943509A1 (en) 2022-01-26
JP2025143396A (ja) 2025-10-01
JP7708741B2 (ja) 2025-07-15
EP3818086A1 (en) 2021-05-12
BR112022004474A2 (pt) 2022-06-21
BR112022004474A8 (pt) 2023-01-17
US20260132219A1 (en) 2026-05-14
TW202123926A (zh) 2021-07-01
PL3818086T3 (pl) 2022-03-14
WO2021048274A1 (en) 2021-03-18
CN113347994A (zh) 2021-09-03
CN113347994B (zh) 2022-09-23

Similar Documents

Publication Publication Date Title
US11208498B2 (en) Treatment and prevention of cancer using HER3 antigen-binding molecules
US20240092937A1 (en) Her3 antigen-binding molecules
TW202328191A (zh) 使用her3抗原結合分子的癌症之治療及預防
HK40026637B (en) Her3 antigen-binding molecules
HK40026637A (en) Her3 antigen-binding molecules
HK40052624B (en) Treatment and prevention of cancer using her3 antigen-binding molecules
HK40052624A (en) Treatment and prevention of cancer using her3 antigen-binding molecules

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240815

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240815

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240815

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240828

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240828

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT APPLICANT REQUEST RECEIVED

Effective date: 20240828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT - OTHER THAN 5.09.01/02/03 DETERMINED NOT COMPLIANT

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250210

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260130

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260211

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260213

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260325